Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma

NCT04850495 · clinicaltrials.gov ↗

PHASE1

Phase

SUSPENDED

Status

38

Enrollment

OTHER

Sponsor class

Stopped Reached accrual limit

Conditions

Diffuse Large B-Cell Lymphoma
Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma

Interventions

DRUG: Cyclophosphamide
DRUG: Doxorubicin Hydrochloride
DRUG: Prednisone
BIOLOGICAL: Rituximab
DRUG: Vincristine Sulfate
DRUG: Zanubrutinib

Sponsor

Yazeed Sawalha